Five-year agreement will underpin campus, online and lifelong learning across the Van Lang ecosystem

TORONTO, Oct. 19, 2026 /PRNewswire/ — D2L, a global leader in learning innovation, today announced that Van Lang Investment and Education Management Group Corporation (Van Lang Education Group, or VLG) has selected D2L Brightspace as a foundation for the next phase of learning innovation across its education ecosystem. VLG has become D2L’s first strategic customer in Vietnam to adopt D2L Brightspace.

VLG operates a group of education institutions in Vietnam, united by a belief that learning should evolve with people throughout their lives. For VLG, digital transformation is not simply about technology. It is about creating better ways for people to learn, connect and grow. With D2L Brightspace, VLG is taking another step toward more personalized, connected and flexible learning–across campuses, online and throughout the lifelong learning journey.

“Our partnership with D2L is not simply an investment in technology; it is an investment in how people learn,” said Assoc. Prof. Dr. Tran Thi My Dieu, President of Van Lang University. “With D2L Brightspace, we aim to create a more personalized, engaging and flexible learning environment–one that empowers our students today and supports lifelong learning for the future.”
 
Following its pilot, VLG plans to launch D2L Brightspace across its campus-based and online learning environments in September 2027, using several D2L solutions, including:

D2L Brightspace: The award-winning learning platform that makes it easier to create interactive and engaging courses, deliver more personalized learning and lift learner outcomes.D2L Lumi: VLG plans to use Lumi Chat and Lumi Tutor to enhance learning experiences for learners and educators. D2L Lumi is built in line with D2L’s responsible AI principles, designed to support ethical standards and privacy.D2L Performance+: An analytics dashboard that provides insights into learner engagement, success and retention, helping instructors make more informed decisions.H5P: A content creation tool that integrates more than 50 interactive content types to help educators deliver more engaging and accessible learning experiences directly within their courses.

“Van Lang Education Group is our first strategic client in Vietnam and that matters for improving educational experiences across the country,” said John Baker, President and CEO, D2L. “They are building an innovative learning ecosystem that spans campuses and lifelong learning. We are going to work closely together to expand opportunities for its students in Vietnam and across Southeast Asia.”

About Van Lang Education Group

Van Lang Education Group (VLG) is an education ecosystem in Vietnam, bringing together education, research, innovation and business.

Through its institutions and partnerships, VLG creates opportunities for people to learn, develop their potential and contribute meaningfully to their communities. VLG is committed to nurturing talent, expanding access to knowledge and strengthening connections between Vietnam and the global community.

The VLG ecosystem includes Van Lang University, Van Lang Global School, Phuong Dong University, Binh Duong Economics and Technology University, Van Lang Saigon College, and US Vietnam Talent International School (UTS).

Van Lang University (VLU) – www.vlu.edu.vn
 Van Lang Global School (VGS) – vgs.edu.vn
 Phuong Dong University (UPD) – www.phuongdong.edu.vn
 Binh Duong Economics and Technology University (BETU) – www.ktkt.edu.vn
 Van Lang Saigon College (VLSC) – vanlangsaigon.edu.vn
 US Vietnam Talent International School (UTS) – utschool.edu.vn

About D2L   
D2L is transforming the way the world learns, helping learners achieve more than they dreamed possible. Working closely with customers all over the world, D2L is on a mission to make learning more inspiring, engaging and human. Find out how D2L helps transform lives and delivers outstanding learning outcomes in K-12, higher education and businesses.

X: @D2L
© 2026 D2L Corporation.

The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L Asia Pte Ltd, D2L India Pvt Ltd, D2L Brasil Soluções de Tecnologia para Educação Ltda and D2L Sistemas de Aprendizaje Innovadores, S. D2 R.L de C.V., and H5P Group AS.

All D2L and H5P marks are owned by the D2L group of companies. Please visit D2L.com/trademarks for a list of D2L marks. All other trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/d2l-signs-first-strategic-vietnam-customer-as-van-lang-education-group-adopts-d2l-brightspace-302912780.html

SOURCE D2L Corporation

Firmable now detects 75,317 technologies across 19 million businesses, including the back-office infrastructure that website-based technographics miss. Every detection provides critical business context and comes with verified decision-maker contacts.

SAN FRANCISCO and MELBOURNE, Australia, Oct. 19, 2026 /PRNewswire/ — Firmable, the AI-native B2B sales platform, today launched Tech Intelligence. It shows revenue teams the software, infrastructure, cloud and AI a company runs, and links it to the company and contact data Firmable already verifies. Name a technology and get back the companies running it and the people who own it, in one step. Tech Intelligence is now available as a paid add-on, in-product, and through the Firmable MCP in Claude, ChatGPT, and Copilot.

Most B2B sales teams know who they want to sell to. Far fewer know what tech those companies already run. So reps open calls blind. They pitch accounts locked into a rival product and miss the migration and refresh moments that create pipeline. In a recent survey by Firmable of US sales teams, 71% ranked a lack of timing and context on a prospect as their biggest headache, ahead of bad contact data. Only 12% said they have a tool that solves it.

Today’s technographics tools weren’t built to close that gap. Most read only a company’s marketing website, and some look at job ads. That picks up analytics tags and the tools a company is hiring for. It misses the back-office systems that matter most to anyone selling into, alongside or against a tech stack: mail, hosting, identity, cloud and self-hosted services. And even when a team finds the right account, it still has to enrich the list in another tool to reach the right person.

“Being AI-native means we can build products that legacy data vendors can’t bolt on,” said Leigh Jasper, co-founder and co-CEO of Firmable. “Tech Intelligence is a good example. Our AI monitors 10 billion internet endpoints every week, reads four kinds of public signals, matches what it finds to 20 million businesses and joins it to verified people. It does that around the clock. You can’t get there by patching an old database. We built our data layer for AI from day one, and that’s why we can ship this depth fast. We launched our MCP in July. Now Tech Intelligence in October. Customers should expect that pace from Firmable.”

Four ways of seeing a tech stack, in one platform

Tech Intelligence combines four detection methods, whereas most providers use one or two. Firmable reviewed 42 technographic and go-to-market data providers. None documented the same combination. Two of the methods, network and infrastructure observations, almost never show up in sales tools.

So sales teams see the back-office tech other tools miss: who hosts a company’s email, which identity provider it uses, and whether it still runs aging on-premises infrastructure. Each detection is matched to Firmable’s company records and verified contacts. The list a rep gets back already names the people to call and what to open with.

Built for teams that sell into the tech stack

Tech Intelligence is built for any B2B team whose next deal depends on what a prospect already runs. That includes software and technology vendors, managed service providers (MSPs), IT services firms and integrators, cybersecurity providers and MSSPs, and resellers and partner teams. It answers four questions those teams ask every day:

Inside the Firmable platform, the package adds ready-made segments built around common buying moments. Teams can also pair a technology detection with Firmable’s buying signals, such as a new Head of IT or a funding round. That surfaces accounts that are both a fit and in motion.

A rep can ask their AI assistant to “find companies in the US running a competitor’s product, with more than 200 employees, and show me the IT decision-makers at each”. They get a verified, ready-to-action list back in one step and can push it straight to a Firmable list or to their CRM.

Transparent confidence, from public-facing data only

Every Tech Intelligence detection carries a high, medium or low confidence score and a last-observed date. Detections are cross-checked across all four methods. Sales teams see how strong the evidence is and when it was last seen, so they don’t have to trust a black-box tag that could be years old.

All of Tech Intelligence is built from public-facing information. Firmable never logs in, never uses credentials and never goes inside a company’s network.

“Sales teams in the US and Canada have no shortage of data. What they’re missing is the context that turns a list into a conversation,” said Chester Thompson, VP, Americas at Firmable. “Tech Intelligence closes that gap. A rep in Chicago or Toronto can see which accounts still run VMware, which ones have switched email providers, and who owns the decision, all before they pick up the phone. For MSPs, IT services firms and channel teams across North America, that means getting to migration and refresh work before the RFP lands. We’re growing fast, and this is exactly the kind of product that wins new logos.”

The launch follows Firmable’s MCP release in July 2026 and keeps up Firmable’s fast product cadence as the company expands across the US and Canada, building on its base in Australia and APAC.

Firmable Tech Intelligence at a glance

What it is: a technology detection product that shows the software, infrastructure, cloud and AI a company runs, joined to verified company and contact data.Coverage: 75,317 technologies across more than 19 million businesses.Methods: deep scans, at vast, AI-enabled scale, of public-facing IT infrastructure as well as traditional website crawling and job-ad extraction.Accuracy: a high, medium or low confidence score and a last-observed date on every detection.Who it’s for: tech vendors, MSPs, IT services firms and integrators, cybersecurity providers and MSSPs, resellers and partner teams.Where to use it: in Claude, ChatGPT, Copilot, and other AI tools via the Firmable MCP, and in the Firmable platform.Markets: the US, Canada, Australia, New Zealand and Southeast Asia.

Get started

Learn more about Firmable Tech Intelligence at firmable.ai/tech-intelligence, or start a free trial of the core platform at app.firmable.com/sign-up.

About Firmable

Firmable is an AI-native B2B sales platform, your AI sales teammate, that helps revenue teams find, understand and connect with the right buyers at the right time. Combining verified company and contact data with technology intelligence, CRM context, buyer intent and agentic AI, Firmable powers go-to-market teams across the US, Canada and Asia-Pacific. firmable.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/firmable-launches-tech-intelligence-showing-b2b-sales-teams-what-their-prospects-actually-run-and-who-to-call-about-it-302913055.html

SOURCE Firmable

SHERIDAN, Wyo., Oct. 19, 2026 /PRNewswire/ — The global tumor ablation market is valued at USD 1.04 billion in 2026 and is projected to reach USD 1.8 billion by 2031, growing at a CAGR of 11.6% over the forecast period (2026–2031), according to a new study by Wissen Research.

Tumor ablation destroys targeted tumor tissue with heat, cold, or other forms of energy while trying to spare the healthy tissue around it. In percutaneous procedures, a physician threads a probe through the skin and into the tumor under imaging guidance, which lowers the risks that come with standard surgery. For patients who are not candidates for surgery, or for whom preserving organ function matters, it is an increasingly important option.

The demand starts with patient numbers. The International Agency for Research on Cancer (IARC) counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects the figure to rise significantly by 2050. A growing population of patients with solid tumors is driving demand for localized treatments that can work alongside surgery, radiation, and systemic therapy or, in specific cases, replace them.

Download Free Sample PDF — Explore Key Market Trends, CAGR & Patent Highlights: https://www.wissenresearch.com/request-a-sample/?report=tumor-ablation-market 

The Probe Is Only Part of the System: Imaging and Planning Software Now Sit Beside the Energy Source

Tumor ablation is moving away from standalone energy delivery devices toward integrated systems. Modern platforms increasingly combine the energy source with CT, ultrasound, MRI, navigation, temperature sensors, and treatment planning software, so the physician can place the probe precisely, watch the treated zone, and plan how far the treatment should extend. CT and ultrasound help position the probe, MRI gives detailed images of the treated area, and software lets the physician define tumor borders before treatment begins. The report describes an industry that is becoming more technology- and software-oriented, with competition shifting toward more efficient image-guided tumor ablation, tighter control of the procedure, and larger, more predictable ablation zones.

Precision matters because physics can work against the treatment. The National Cancer Institute (NCI) notes that radiofrequency ablation, microwave ablation, and cryoablation are used for localized liver cancer, but tumor size and location can limit how well thermal ablation works. When a tumor sits close to a large blood vessel, flowing blood can carry heat away from the treatment area, a heat-sink effect that reduces effectiveness.

Beyond Heat: Freezing, Focused Ultrasound, and Electrical Pulses Widen the Toolkit

Radiofrequency ablation remained a leading technology in 2025 on the strength of its long clinical track record and wide availability, and the NCI lists it among the local treatment options for liver malignancies. Microwave ablation is gradually gaining ground because it can offer higher temperatures, larger ablation areas, and simultaneous treatment through multiple devices, while cryoablation, which destroys tissue by freezing and thawing, is getting stronger in kidney and prostate cancer.

Other approaches are broadening what can be treated. Irreversible electroporation (IRE) uses short electrical pulses instead of heat to disrupt cells, and is being explored where conventional heating is difficult, such as near sensitive structures. High-intensity focused ultrasound (HIFU) delivers energy through concentrated ultrasound signals. Both remain more specialized than the established thermal methods, and the report notes that the state of the technology and the available evidence vary from one application to another, even as ablation spreads beyond the liver and kidney to other solid tumors.

Talk to an Industry Analyst — Request Custom Country Segmentation & Technology Deep-Dives: https://www.wissenresearch.com/request-customization/?report=tumor-ablation-market 

What’s Fueling Growth in the Tumor Ablation Market

A larger cancer patient population: More patients with solid tumors are creating demand for localized treatments alongside surgery, radiotherapy, and systemic therapy.Preference for minimally invasive procedures: Ablation can be performed through the skin, which makes it an option when surgery is not possible or when treatment must avoid harming surrounding healthy tissue.Wider use of image-guided techniques: CT, ultrasound, and MRI allow precise probe placement, treatment planning, and monitoring of the ablation zone.Better ablation equipment: Improvements in microwave equipment and electrodes, cryoprobes, HIFU systems, and electroporation technology give physicians finer control over tumor destruction.More tumor types in play: Ablation is being applied or researched in liver, kidney, lung, prostate, breast, bone, and other localized tumors.Demand for organ-sparing treatment: Destroying a localized tumor requires less extensive intervention and preserves nearby healthy tissue.

Challenges Facing the Tumor Ablation Market

The central challenge is destroying the whole tumor while protecting what is next to it. Results depend on the tumor’s size, shape, location, and tissue properties, and on how close it sits to vital structures. Tumors that are not fully destroyed can survive at the treatment margin, raising the risk of local recurrence and the need for repeat procedures or additional treatment. Tumors near bile ducts, airways, nerves, and intestines can force physicians to reduce the energy they deliver, and inconsistent probe placement can leave tumor tissue behind. That is why imaging, probe positioning, treatment planning, and monitoring have to be clear and dependable.

Adoption has its own hurdles. Using advanced imaging technology involves regulatory requirements, the availability of clinical evidence, and the level of physician training, and technologies such as irreversible electroporation, HIFU, and laser ablation are still developing.

Recent Strategic Developments in the Tumor Ablation Market

In August 2026, IceCure Medical Ltd. of Israel entered into an exclusive distribution agreement with Scovas Medical for its ProSense cryoablation systems in the Netherlands. The agreement expanded ProSense commercialization for breast cancer and interventional oncology, while the Netherlands-based THERMAC trial advanced to Phase III, supporting further clinical adoption of cryoablation.

In May 2026, AngioDynamics, Inc. of the United States announced that Palmetto GBA had issued a final Medicare coverage determination for irreversible electroporation using the NanoKnife System for selected prostate cancer cases and metastatic colorectal cancer to the liver. The coverage took effect July 5, 2026, supporting broader reimbursement and patient access to non-thermal tumor ablation.

One development opens a new market for cryoablation, and the other makes a non-thermal technique easier for patients to access.

Key Insights from Tumor Ablation Market Analysis

Radiofrequency ablation held a leading position by technology type in 2025, supported by extensive clinical experience, wide availability, and its use in liver, kidney, and lung tumors.Systems held a leading position by product type in 2025, reflecting rising uptake of energy-based solutions for minimally invasive tumor treatment. The segment spans radiofrequency, microwave, cryoablation, and irreversible electroporation systems, and manufacturers are focusing on energy delivery, control of the treatment zone, probe and electrode configuration, cooling, monitoring, and compatibility with image guidance.North America held the largest regional share in 2025, supported by established healthcare infrastructure, strong interventional radiology capabilities, high acceptance of minimally invasive oncology treatment, and well-known device makers. The United States accounts for most of the region’s market, with many cancer treatment centers, skilled specialists, clinical research infrastructure, and strict medical-device regulation.Asia Pacific is the fastest-growing region, driven by a growing number of cancer patients and rapid healthcare development, with China, Japan, South Korea, and India adopting interventional oncology and image-based treatment techniques.The market is moderately consolidated, with established medical-device companies competing alongside specialized ablation technology manufacturers.

Key Players in the Tumor Ablation Market

Leading companies in the tumor ablation market are focusing on radiofrequency and microwave energy delivery, cryoablation, HIFU, irreversible electroporation, image-guided intervention, navigation, treatment planning, and expansion into additional solid-tumor applications.

The report names Medtronic plc (Ireland), Boston Scientific Corporation (US), Johnson & Johnson (US), AngioDynamics, Inc. (US), and IceCure Medical Ltd. (Israel) as the top five players, with established positions across radiofrequency ablation, microwave ablation, cryoablation, and other interventional oncology technologies. Competition turns on energy-delivery performance, treatment precision, probe design, the predictability of the ablation zone, clinical evidence, regulatory approvals, imaging integration, procedural efficiency, and physician adoption.

Other companies profiled in the report include Stryker Corporation (US), Bioventus Inc. (US), CONMED Corporation (US), Merit Medical Systems, Inc. (US), Siemens Healthineers AG (Germany), and Olympus Corporation (Japan). The report also covers Terumo Corporation, EDAP TMS S.A., Insightec Ltd., Theraclion SA, Chongqing Haifu Medical Technology Co., Ltd., Alpinion Medical Systems Co., Ltd., STARmed Co., Ltd., SonaCare Medical, LLC, HealthTronics, Inc., and Novian Health, Inc., among others.

Regional Analysis and Growth Opportunities

North America leads the tumor ablation market, supported by advanced healthcare infrastructure, growing interventional radiology capacity, high spending on cancer treatment, wide adoption of minimally invasive procedures, and leading manufacturers. The U.S. has a well-structured regulatory framework for medical devices and interventional oncology technologies, in which regulators approve and clear many ablation systems for specific medical applications. The country is also a key center for clinical studies and procedure development in microwave ablation, cryoablation, radiofrequency ablation, HIFU, and electroporation.

Asia Pacific is the fastest-growing region, reflecting a growing number of cancer patients and rapid development of healthcare systems. China, Japan, South Korea, and India are the most important markets, and all four are active in adopting new interventional oncology techniques and image-based technologies for treatment.

Europe, Latin America, and the Middle East & Africa complete the report’s regional coverage.

Market Segmentation Snapshot

The global tumor ablation market is segmented across product type, technology type, procedure type, application type, end user type, and region:

By Product Type:Systems (Radiofrequency Ablation Systems, Microwave Ablation Systems, Cryoablation Systems, Irreversible Electroporation Systems, Other Systems)Probes/Electrodes (Radiofrequency Ablation Probes, Microwave Ablation Probes, Other Probes/Electrodes)Consumables & AccessoriesOther Consumables & AccessoriesBy Technology Type:Radiofrequency AblationMicrowave AblationCryoablationIrreversible ElectroporationOther TechnologiesBy Procedure Type:Laparoscopic AblationPercutaneous AblationSurgical AblationBy Application Type:Lung CancerKidney CancerBone CancerLiver CancerOther ApplicationsBy End User Type:Hospitals & ClinicsCancer Care CentresAmbulatory Surgery CentresOther End UsersBy Region:North AmericaEuropeAsia-PacificLatin AmericaMiddle East & Africa

Frequently Asked Questions

Q: What is the size of the tumor ablation market? A: The global tumor ablation market is estimated at USD 1.04 billion in 2026 and is projected to reach USD 1.8 billion by 2031.

Q: What is the growth rate of the tumor ablation market? A: The tumor ablation market is projected to grow at a CAGR of 11.6% between 2026 and 2031.

Q: What is tumor ablation? A: Tumor ablation refers to minimally invasive procedures that destroy targeted tumor tissue using thermal, non-thermal, or energy-based techniques, including radiofrequency energy, microwave energy, cryogenic energy, focused ultrasound, laser energy, or electrical pulses, while minimizing damage to surrounding healthy tissue. Depending on the technology, procedures may be performed percutaneously, laparoscopically, or through other image-guided minimally invasive approaches.

Q: Which cancers are treated with tumor ablation? A: Established applications include liver, kidney, lung, and prostate tumors, with growing use in breast, bone, and other solid tumors. The state of the technology and the availability of clinical evidence vary from one application to another.

Q: Which technology leads the tumor ablation industry? A: Radiofrequency ablation held a leading position by technology type in 2025, supported by extensive clinical experience and wide availability, while microwave ablation is gradually gaining ground.

Q: Which product type leads the tumor ablation market? A: Systems held a leading position by product type in 2025, reflecting rising uptake of energy-based solutions for minimally invasive tumor treatment.

Q: Which region leads the tumor ablation market? A: North America held the largest share of the tumor ablation industry in 2025, while Asia Pacific is the fastest-growing region through 2031.

Q: Who are the top players in the tumor ablation market? A: Leading companies in the tumor ablation market include Medtronic plc, Boston Scientific Corporation, Johnson & Johnson, AngioDynamics, Inc., and IceCure Medical Ltd.

Ablation began as a way to destroy a tumor with a probe. The report points to a market where the probe is only part of the system, and imaging, planning, monitoring, and clinical evidence matter as much as the energy source. For manufacturers, the work ahead is delivering more predictable ablation zones near vital structures and building the evidence and training that newer techniques need.

View Pricing & License Options — Unlock Full Market Sizing & Competitive Benchmarking: https://www.wissenresearch.com/market-research-reports-pricings/tumor-ablation-market 

Expert Profile | Mayur Jain, Wissen Research 

Mayur Jain is a Research Expert at Wissen Research with multidomain expertise with more than 12+ years of experience in market research industry. 

Email: mayur@wissenresearch.com
LinkedIn:  https://www.linkedin.com/in/mayur-jain-0190542a/ 

About Wissen Research

Wissen Research is a global market intelligence and consulting firm specializing in healthcare, life sciences, technology, and emerging industries. The company provides data-driven insights, strategic market analysis, and industry forecasts to help organizations make informed business decisions and identify new growth opportunities across global markets

Company Contact:

Wissen Research LLC,
Gould St, Ste R,
Sheridan, WY 82801,
Phone: (+1) 510 240 9853
Email: info@wissenresearch.com
Website: https://www.wissenresearch.com/
Blog: https://www.wissenresearch.com/insights/
LinkedIn: https://www.linkedin.com/company/wissen-research 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tumor-ablation-market-set-to-surge-to-us-1-8-billion-by-2031–growing-at-11-6-cagr-wissen-research-302913088.html